Sunday, April 10, 2022 6:34:38 AM
You said:
I agree that these changes need to be introduced in accordance with the Good Manufacturing Practices (“GMP”). However i believe that the changes to the manufacturing of the ATMP must be supported by the data generated in a comparability exercise. IMO, this is valid for both investigational ATMPs and authorised ATMPs.
Here is comment on the ‘Questions and Answers’ document (EMA) I found on BioSlice Blog, published by the EU Life Sciences team at Arnold & Porter.
They follow and comment on legal and regulatory developments within the European life sciences community, focusing upon pharmaceuticals, biotech, medical devices and diagnostics.
For those interested here is the full article:
EMA Guidance on Comparability Exercise for ATMPs
By Alexander Roussanov & Lincoln Tsang on December 19, 2019
On 13 December 2019, the European Medicines Agency (“EMA”) published a Questions and Answers document (“Q&A”) providing guidance on the conduct of comparability exercise for advanced therapy medicinal products (“ATMPs”). The Q&A addresses various regulatory questions that arise in situations in which companies developing or marketing ATMPs introduce changes to the manufacturing process and need to generate related comparability data.
Background
EMA’s experience suggests that changes to the manufacturing of ATMPs are “frequent” and even more so in the development of the medicinal product. These changes need, however, to be introduced in accordance with the Good Manufacturing Practices (“GMP”). Moreover, the changes may require a variation of the marketing authorisation for authorised ATMPs or substantial amendments to the clinical trial protocol for ATMPs used in clinical trials.
In addition, the changes to the manufacturing of the ATMP must be supported by the data generated in a comparability exercise. This exercise should focus on the characteristics of the ATMP prior and after the introduction of the manufacturing change. This is valid for both investigational ATMPs and authorised ATMPs.
The position of the EMA is that changes to the manufacturing of the ATMP should not undermine or impact adversely the quality, efficacy or safety of the medicinal product or the related risk-benefit balance. The objective of the comparability exercise is to facilitate the assessment and demonstration of this.
EMA guidance
The Q&A provides answers to general regulatory questions, as well as specific guidance for cell-based ATMPs and vector-based gene therapy medicinal products. The position of the EMA is that the comparability exercise for cell-based ATMPs cannot be based solely on the characterisation of the phenotypic markers related to purity confirming a heterogeneity profile. The comparability assessment for this type of ATMPs should, therefore, cover the dynamic nature of the product and the mechanisms relating to the product’s metabolism, differentiation stage, structural organisation and interactions.
Interplay with ICH Q5E
The ICH Q5E guidance issued by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (“ICH”) addresses the comparability of biotechnology and biological medicinal products. This guidance does not, however, apply to ATMPs due to the inherent variability of the starting materials for cell/tissue-based products, as well as the complex biological features and manufacturing processes of the ATMPs in general.
The general principles of ICH Q5E do, however, apply to the conduct of the comparability exercise for ATMPs:
- stepwise conduct of the comparability exercise;
- focus on the manufacturing process steps that are most appropriate
top detect change;
- use of suitable and sufficiently sensitive analytical methods;
- generation of data enabling to reach a conclusion on the
comparability.
EMA clarifies that the ICH Q5E guidance is particularly relevant for vector-based gene therapies as they are more closely related to biotechnology medicinal products in terms of manufacturing process.
Other key elements of the Q&A
The Q&A highlights a number of additional key considerations for the conduct of the comparability exercise:
- requirement to conduct a comparability exercise for any changes to
the manufacturing process of the ATMP occurring at any stage of the
development, including introduction of new manufacturing site;
- use of the risk-based approach in the determination of the amount
of comparability data that needs to be generated:
- high risk changes or changes to the manufacturing of
authorised ATMPs or ATMPs in pivotal clinical trials require
the generation of more comparability data;
- only critical changes to the manufacturing of the starting
material with impact on the manufacturing of the finished
product require the conduct of a comparability exercise.
- requirement to compare both the manufactured products and the
manufacturing processes themselves;
- use of appropriate analytical tools for the comparability exercise;
- preferred approach for the comparability exercise:
- side by side testing vs comparison of post-change data with
pre-change historical data.
- potential use of healthy donors’ materials;
- need for stability studies and acceptability of statistical
approaches;
- determination of the number of batches to be used in the
comparability study.
As a general rule, the EMA discourages companies to introduce changes to the manufacturing process or the final ATMP during the conduct of clinical pivotal clinical trials. This is due to the complexity of the comparability exercise in such situations and the potential impact on the validity of the clinical data. If the changes are unavoidable, companies are advised to seek the EMA’s scientific advice.
https://www.biosliceblog.com/2019/12/ema-guidance-on-comparability-exercise-for-atmps/
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
FEATURED Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • Apr 25, 2024 8:52 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM